Your Product

Your Product

Back to main menu

Your Product

Services tailored to your product, ensuring the right development path, scalable processes, and consistent manufacturing outcomes.

Learn more
Your Stage

Your Stage

Back to main menu

Your Stage

At each stage, new challenges emerge. A single team and site ensure continuity and consistent execution across the product lifecycle.

Learn more
Our Services

Our Services

Back to main menu

Our Services

Integrated CDMO services designed for seamless progression from development through commercial manufacturing, under global regulatory standards.

Learn more
Resources

Resources

Back to main menu

Resources

Technical insights, practical guidance, and applied expertise to support decision‑making at every stage.

See all resources
About Us

About Us

Back to main menu

About Us

An overview of Groupe PARIMA, our mission, and our expertise in supporting the pharmaceutical industry.

Learn more
    En
    English
    Contact us

    Formulation Development

    We develop non‑sterile formulations designed for consistent performance and reliable GMP manufacturing.

    Drug Manufacturing banner

    Formulations designed for GMP

    We design robust non‑sterile dosage forms that translate into consistent manufacturing.

    Formulation development sets product performance, stability, and manufacturability. Groupe PARIMA develops liquid, suspension, and semi‑solid formulations using QbD to predefine objectives and link critical quality attributes, excipient selection, process parameters, and a lifecycle control strategy that supports scale‑up and validation readiness.

    Talk to our experts

    We turn formulation targets into manufacturable liquids, suspensions, and semi‑solids with defined CQAs and a control strategy.

    Expertise in Formulation

    We develop non‑sterile products with a QbD approach that defines CQAs, process parameters, and a control strategy for scale‑up and validation readiness.

    Card 01

    De novo development

    Design a new formulation around your API and target product profile, with excipient selection and process establishment built for GMP manufacturing.

    Card 02

    Deformulation

    Reformulation of existing drug products to support reformulation via the 505(b)(2) pathway and development of comparable formulations under 505(j).

    Card 03

    Optimization

    Strengthen an existing formulation by optimizing excipients and process variables using DoE to improve stability, manufacturability, and batch‑to‑batch consistency.

    Card 04

    Scale-UP

    Studies supporting process scale‑up and equipment adaptation to ensure successful technology transfer across production.

    Built for performance and transfer

    We develop non‑sterile liquids, suspensions, and semi‑solids using QbD to define CQAs, critical process parameters, and a lifecycle control strategy.

    01
    Card 01

    Strategic Excipient Selection

    Select excipients based on functionality, API compatibility, and target product performance.

    02
    Card 02

    Controlled Rheology & Stability

    Optimize viscosity and physical stability to maintain consistent performance through shelf life.

    03
    Card 03

    Process Development & Scale‑Up

    Define process parameters that transfer to GMP equipment with predictable results.

    04
    Card 04

    Control Strategy Definition

    Set in‑process controls and acceptance criteria to support validation readiness and ongoing consistency.

    05
    Card 05

    Timeline & Clinical Trial Readiness

    Pre‑formulation outputs are aligned with clinical supply goals to support stage readiness and key regulatory milestones.

    06
    Card 06

    Early Manufacturing Insights

    Development decisions integrate manufacturing considerations early to support scalable processes and smooth technology transfer.

    Resources

    Explore practical guidance on non‑sterile formulation development, scale‑up, and control strategy.

    Groupe PARIMA
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    Groupe PARIMA
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Groupe PARIMA
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more
    Groupe PARIMA
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    Groupe PARIMA
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Groupe PARIMA
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more

    See all Resources

    Contact us

    Have a formulation project in progress?

    Partner with Groupe PARIMA to develop and transfer non‑sterile formulations using QbD, fit‑for‑purpose analytics, and a control strategy designed for reliable GMP manufacturing.